CN1769286B - 一种治疗鼻腔分泌过度和慢阻肺的化合物以及药物组合物 - Google Patents
一种治疗鼻腔分泌过度和慢阻肺的化合物以及药物组合物 Download PDFInfo
- Publication number
- CN1769286B CN1769286B CN2005101092923A CN200510109292A CN1769286B CN 1769286 B CN1769286 B CN 1769286B CN 2005101092923 A CN2005101092923 A CN 2005101092923A CN 200510109292 A CN200510109292 A CN 200510109292A CN 1769286 B CN1769286 B CN 1769286B
- Authority
- CN
- China
- Prior art keywords
- compound
- cyclopentyl
- phenyl
- azabicyclo
- octane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 92
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 24
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims description 17
- 206010039083 rhinitis Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 12
- -1 (2-cyclopentyl-2-hydroxyl-2-phenyl) oxyethyl group Chemical group 0.000 claims description 37
- 239000007922 nasal spray Substances 0.000 claims description 26
- 239000007923 nasal drop Substances 0.000 claims description 25
- 229940097496 nasal spray Drugs 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 18
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 12
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 10
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- LSLYOANBFKQKPT-UHFFFAOYSA-N fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 claims description 7
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 229940125773 compound 10 Drugs 0.000 claims description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 3
- 239000005844 Thymol Substances 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 3
- 229960004217 benzyl alcohol Drugs 0.000 claims description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 3
- 229960003742 phenol Drugs 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 235000010199 sorbic acid Nutrition 0.000 claims description 3
- 239000004334 sorbic acid Substances 0.000 claims description 3
- 229940075582 sorbic acid Drugs 0.000 claims description 3
- 229960000790 thymol Drugs 0.000 claims description 3
- 239000000341 volatile oil Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 201000009151 chronic rhinitis Diseases 0.000 claims description 2
- 229940125782 compound 2 Drugs 0.000 claims description 2
- 201000009240 nasopharyngitis Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 27
- 239000000443 aerosol Substances 0.000 abstract description 23
- 239000007921 spray Substances 0.000 abstract description 18
- 239000000843 powder Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000001684 chronic effect Effects 0.000 abstract description 6
- 230000000414 obstructive effect Effects 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 210000004400 mucous membrane Anatomy 0.000 abstract description 4
- 125000001453 quaternary ammonium group Chemical group 0.000 abstract description 3
- DDTVVMRZNVIVQM-UHFFFAOYSA-N 2-(1-azabicyclo[2.2.2]octan-3-yloxy)-1-cyclopentyl-1-phenylethanol;hydrochloride Chemical compound Cl.C1N(CC2)CCC2C1OCC(O)(C=1C=CC=CC=1)C1CCCC1 DDTVVMRZNVIVQM-UHFFFAOYSA-N 0.000 abstract description 2
- 206010014561 Emphysema Diseases 0.000 abstract 4
- 210000004379 membrane Anatomy 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000012466 permeate Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 30
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- 239000013642 negative control Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 210000003928 nasal cavity Anatomy 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 206010039101 Rhinorrhoea Diseases 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 210000002850 nasal mucosa Anatomy 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 208000010753 nasal discharge Diseases 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 208000006673 asthma Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 7
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000001331 nose Anatomy 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 6
- 235000010234 sodium benzoate Nutrition 0.000 description 6
- 239000004299 sodium benzoate Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 206010021703 Indifference Diseases 0.000 description 5
- 102000004317 Lyases Human genes 0.000 description 5
- 108090000856 Lyases Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229960000935 dehydrated alcohol Drugs 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 239000013067 intermediate product Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 206010039085 Rhinitis allergic Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 201000009961 allergic asthma Diseases 0.000 description 4
- 201000010105 allergic rhinitis Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229960004495 beclometasone Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 4
- 229940089256 fungistat Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 229940050176 methyl chloride Drugs 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- SRBFZHDQGSBBOR-QMKXCQHVSA-N alpha-L-arabinopyranose Chemical compound O[C@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-QMKXCQHVSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003957 anion exchange resin Substances 0.000 description 3
- 230000001078 anti-cholinergic effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 229960001361 ipratropium bromide Drugs 0.000 description 3
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- ATEBGNALLCMSGS-UHFFFAOYSA-N 2-chloro-1,1-difluoroethane Chemical compound FC(F)CCl ATEBGNALLCMSGS-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 101100028789 Arabidopsis thaliana PBS1 gene Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 2
- 229940099364 dichlorofluoromethane Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- BCCOBQSFUDVTJQ-UHFFFAOYSA-N octafluorocyclobutane Chemical compound FC1(F)C(F)(F)C(F)(F)C1(F)F BCCOBQSFUDVTJQ-UHFFFAOYSA-N 0.000 description 2
- 235000019407 octafluorocyclobutane Nutrition 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
- 229940029284 trichlorofluoromethane Drugs 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- LMUJEWVKOCYOQL-UHFFFAOYSA-M 1-cyclopentyl-2-[(1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl)oxy]-1-phenylethanol bromide Chemical compound [Br-].C1C[N+](C)(C2)CCC1C2OCC(O)(C=1C=CC=CC=1)C1CCCC1 LMUJEWVKOCYOQL-UHFFFAOYSA-M 0.000 description 1
- YAHCEHSKYMREOS-UHFFFAOYSA-N 1-cyclopentyloxyethylbenzene Chemical compound C=1C=CC=CC=1C(C)OC1CCCC1 YAHCEHSKYMREOS-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- WCTDPBQDNDDPNN-UHFFFAOYSA-N 2-aminoacetic acid;sodium Chemical compound [Na].[Na].NCC(O)=O WCTDPBQDNDDPNN-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical compound C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067994 Mucosal atrophy Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 101100489867 Mus musculus Got2 gene Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 229940082436 benzalkonium chloride 3 mg Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 1
- 229960001120 levocabastine Drugs 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
化合物V | 12mg |
苯扎氯铵 | 3mg |
H<sub>2</sub>O | 10ml |
化合物II | 2.5mg |
非诺特罗 | 10mg |
苯扎氯铵 | 5mg |
H<sub>2</sub>O | 10ml |
化合物I | 3.33mg |
苯扎氯铵 | 5.00mg |
1N HCl(pH 4-6) | 0.018mg |
纯H<sub>2</sub>O | 2.0ml |
化合物IV | 0.28g |
丙二醇 | 42g |
无水乙醇 | 210g |
2-氟-2氯甲烷 4-氟-2氯乙烷 | 231g 971g |
化合物V | 0.28g |
丙二醇 | 35g |
无水乙醇 | 382g |
2-氟-2氯甲烷 和4-氟-2氯乙烷) | 540g 443g |
化合物III | 0.05 g |
乳糖 | 98.95g |
苯甲酸钠 | 1.0g |
化合物V | 0.05g |
葡聚糖 | 99.45g |
硬脂酸镁 | 0.5g |
Claims (6)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101092923A CN1769286B (zh) | 2005-10-20 | 2005-10-20 | 一种治疗鼻腔分泌过度和慢阻肺的化合物以及药物组合物 |
PCT/CN2006/002638 WO2007045151A1 (fr) | 2005-10-20 | 2006-10-09 | Composes et compositions pharmaceutiques les comprenant pour le traitement de l'hypersecretion de la cavite nasale et de la bronchopneumopathie chronique obstructive |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101092923A CN1769286B (zh) | 2005-10-20 | 2005-10-20 | 一种治疗鼻腔分泌过度和慢阻肺的化合物以及药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1769286A CN1769286A (zh) | 2006-05-10 |
CN1769286B true CN1769286B (zh) | 2010-10-06 |
Family
ID=36750859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005101092923A Active CN1769286B (zh) | 2005-10-20 | 2005-10-20 | 一种治疗鼻腔分泌过度和慢阻肺的化合物以及药物组合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1769286B (zh) |
WO (1) | WO2007045151A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101856327B (zh) * | 2009-04-08 | 2012-02-22 | 北京银谷世纪药业有限公司 | 一种苯环喹溴铵定量吸入气雾剂及制备方法 |
CN111377920B (zh) * | 2018-12-27 | 2021-10-26 | 银谷制药有限责任公司 | 一种含有季铵基团的奎宁类化合物的精制方法 |
CN115487180A (zh) * | 2022-09-01 | 2022-12-20 | 江苏联环药业股份有限公司 | 一种用于治疗变应性鼻炎的药物组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1475214A (zh) * | 2002-08-16 | 2004-02-18 | 成都力思特制药有限公司 | 盐酸戊乙奎醚的应用 |
CN1532196A (zh) * | 2003-03-21 | 2004-09-29 | 北京小伙伴医药生物技术有限公司 | 一种含有季铵基团的奎宁类化合物及其制法和药物用途 |
CN1709891A (zh) * | 2005-06-16 | 2005-12-21 | 成都力思特制药股份有限公司 | 一种药物化合物及其组合物和在制药中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7521559B2 (en) * | 2004-09-15 | 2009-04-21 | Shuqiang Zhao | Quinuclidine compounds having quaternary ammonium group, its preparation method and use as blocking agents of acetylcholine |
CN1813768A (zh) * | 2005-11-18 | 2006-08-09 | 成都力思特制药股份有限公司 | 治疗呼吸系统疾病的药用组合物及其在制药中的应用 |
-
2005
- 2005-10-20 CN CN2005101092923A patent/CN1769286B/zh active Active
-
2006
- 2006-10-09 WO PCT/CN2006/002638 patent/WO2007045151A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1475214A (zh) * | 2002-08-16 | 2004-02-18 | 成都力思特制药有限公司 | 盐酸戊乙奎醚的应用 |
CN1532196A (zh) * | 2003-03-21 | 2004-09-29 | 北京小伙伴医药生物技术有限公司 | 一种含有季铵基团的奎宁类化合物及其制法和药物用途 |
CN1709891A (zh) * | 2005-06-16 | 2005-12-21 | 成都力思特制药股份有限公司 | 一种药物化合物及其组合物和在制药中的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2007045151A1 (fr) | 2007-04-26 |
CN1769286A (zh) | 2006-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2202352T3 (es) | Derivados de 5-(2-imidazolinilamino)bencimidazol, su preparacion y uso como agonistas de los adrenorreceptores alfa-2. | |
EP2736491B1 (en) | Bepotastine compositions | |
TW438595B (en) | Preparation for transmucosal administration containing physiologically active peptide | |
US8450339B2 (en) | Compositions for treatment of common cold | |
CN101585835B (zh) | 一组苯环喹溴铵光学异构体及其组合物的制备方法与应用 | |
CA2540174A1 (en) | Aerosol formulation for inhalation, containing an anticholinergic agent | |
JPH11511758A (ja) | 鼻腔用ステロイドと抗ヒスタミン剤を含む鼻腔内噴霧薬 | |
JP2003511417A (ja) | 局所的鼻疾患治療 | |
US20060110449A1 (en) | Pharmaceutical composition | |
TW406077B (en) | 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists | |
CA2495275A1 (en) | Aerosol formulation for inhalation comprising an anticholinergic agent | |
PT735877E (pt) | Compostos de 6-(2-imidazolinilamino)quinoxalina uteis como agonistas do receptor alfa-2 adrenergico | |
KR100687806B1 (ko) | 특정약의 질산에스테르 및 질산염 | |
CN1769286B (zh) | 一种治疗鼻腔分泌过度和慢阻肺的化合物以及药物组合物 | |
US7531528B2 (en) | Formulation containing anti-inflammatory androstane derivatives | |
DE3601923A1 (de) | Nasal applizierbares arzneimittel, verfahren zu seiner herstellung und seine verwendung | |
JPH09511483A (ja) | α−2−アドレノセプター作動剤として有用な6−(2−イミダゾリニルアミノ)キノリン化合物 | |
JP2005533076A (ja) | ムコ多糖及びプロピレングリコールを含む鼻用組成物 | |
JPH10298107A (ja) | 医薬組成物 | |
ZA200704378B (en) | Pharmaceutical compounds and compositions | |
CN106390128B (zh) | β-肾上腺素能反向激动剂用于戒烟的用途 | |
JP2001519828A (ja) | α▲下2▼−アドレナリン受容体作動薬として有用な5−(2−イミダゾリニルアミノ)ベンゾイミダゾール化合物類 | |
JPH0710752A (ja) | アレルギー性及び自己免疫疾患治療用新規医薬組成物 | |
SK69699A3 (en) | 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists | |
CN101264081B (zh) | 治疗肺纤维化的化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING YINGU CENTURY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CACHET PHARMACEUTICAL CO LTD Effective date: 20110107 Free format text: FORMER OWNER: BEIJING SHIQIAO BIOPHARMACEUTICAL CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100080 1805, YINGU BUILDING, NO. 9, N. 4TH RING WEST ROAD, HAIDIAN DISTRICT, BEIJING TO: 100190 2409, YINGU BUILDING, NO. 9, N. 4TH RING WEST ROAD, HAIDIAN DISTRICT, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110107 Address after: 100190 Beijing city Haidian District North Fourth Ring Road No. 9 Yingu building 2409 Patentee after: BEIJING YINGU CENTURY PHARMACY Co.,Ltd. Address before: 100080 Beijing city Haidian District North Fourth Ring Road No. 9 Yingu building 1805 Co-patentee before: BEIJING SCIECURE PHARMACEUTICAL Co.,Ltd. Patentee before: CACHET PHARMACEUTICAL Co.,Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound and pharmaceutical composition for treating nasal oversecreation and chronic obstructive pulmonary disease Effective date of registration: 20110628 Granted publication date: 20101006 Pledgee: Beijing's first investment Company Limited by Guarantee Pledgor: BEIJING YINGU CENTURY PHARMACY Co.,Ltd. Registration number: 2011990000247 |
|
C56 | Change in the name or address of the patentee |
Owner name: YINGU PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: BEIJING YINGU CENTURY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 100190 Beijing city Haidian District North Fourth Ring Road No. 9 Yingu building 2409 Patentee after: YINGU PHARMACEUTICAL Co.,Ltd. Address before: 100190 Beijing city Haidian District North Fourth Ring Road No. 9 Yingu building 2409 Patentee before: BEIJING YINGU CENTURY PHARMACY Co.,Ltd. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20141028 Granted publication date: 20101006 Pledgee: Beijing first financing Company limited by guarantee Pledgor: YINGU PHARMACEUTICAL Co.,Ltd. Registration number: 2011990000247 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20141028 Registration number: 2011990000247 Pledgee after: Beijing first financing Company limited by guarantee Pledgee before: Beijing's first investment Company Limited by Guarantee Change date: 20141028 Registration number: 2011990000247 Pledgor after: YINGU PHARMACEUTICAL Co.,Ltd. Pledgor before: BEIJING YINGU CENTURY PHARMACY Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No.18a, No.13, Jingsheng South 4th Street, Jinqiao Science and technology industrial base, Tongzhou Park, Zhongguancun Science and Technology Park, Tongzhou District, Beijing Patentee after: YINGU PHARMACEUTICAL Co.,Ltd. Address before: 2409, Yingu Building, No. 9 North Fourth Ring West Road, Haidian District, Beijing, 100190 Patentee before: YINGU PHARMACEUTICAL Co.,Ltd. |